RxDoctor Payments Data

Mukti Aich, MD

Family Medicine · Ocala, FLNPI 1609038082

Payments from drug & device makers

$964in general payments, 2019–2025

Across 50 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$143
  • Astellas Pharma US Inc$131
  • Exact Sciences$125
  • Pfizer$123
  • Novo Nordisk$104
  • Lilly USA, LLC$67
  • plus $272 from 12 others

What the payments were for

  • Food & beverage$964100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$964 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$156,849
Medicare patients
407
Services billed
2,447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab14$141,969
OzempicSemaglutide87$127,328
MounjaroTirzepatide66$74,632
JanuviaSitagliptin Phosphate35$48,572
EliquisApixaban34$36,721
JardianceEmpagliflozin21$31,746
TrulicityDulaglutide20$31,201
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$18,866
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$16,585
Breo ElliptaFluticasone/Vilanterol15$8,471
Humalog Kwikpen U-100Insulin Lispro11$5,441
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$5,420
Incruse ElliptaUmeclidinium Bromide12$4,134
Pregabalin47$3,657
SynthroidLevothyroxine Sodium40$3,172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$104$127,32887 claims
Lilly USA, LLCMounjaro, Trulicity$67$105,83386 claims
MerckJanuvia$19$48,57235 claims
PfizerEliquis, Paxlovid$123$38,12950 claims
Boehringer IngelheimJardiance$21$31,74621 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$24$29,18948 claims
AbbVieSynthroid, Armour Thyroid$143$4,11952 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →